Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)

v3.3.1.900
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Series A Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock
Additional Paid-In Capital
Accumulated other comprehensive income [Member]
Accumulated Deficit
Total
Beginning balance at Dec. 31, 2013 $ 10,108 $ 0 $ 0 $ 3,502 $ 0 $ (12,335) $ (8,833)
Beginning balance, shares at Dec. 31, 2013 7,046 279 0        
Conversion of series A convertible stock, Amount $ (10,108) $ 1   10,107     10,108
Conversion of series A convertible stock, Shares (7,046) 721          
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Amount     $ 116 (1,596)     (1,480)
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Shares     115,907        
Exercise of common stock options, Amount     $ 1 115     116
Exercise of common stock options, Shares     1,087        
Stock based compensation       38     38
Issuance of common stock and warrants in January 2014, Amount     $ 6 (6)     0
Issuance of common stock and warrants in January 2014, Shares     5,500        
Unrealized gain on marketable securities, net of tax         236   236
Series A preferred stock issued in the merger with RFS Pharma, LLC, Amount $ 178,218           0
Series A preferred stock issued in the merger with RFS Pharma, LLC, Shares 1,000            
Stock options issued in the merger with RFS Pharm, LLC       6,565     6,565
Net loss           (99) (99)
Ending balance at Dec. 31, 2014 $ 178,218 $ 1 $ 123 18,725 236 (12,434) $ 6,651
Ending balance, shares at Dec. 31, 2014 1,000 1,000 122,494       122,494
Exercise of stock options   $ 182 $ 0 23     $ 23
Conversion of Series A and Series B convertible shares to common stock, Amount $ (178,218) $ (1) $ 546 177,673     178,218
Conversion of Series A and Series B convertible shares to common stock, Shares (1,000) (1,000) 545,844        
Stock based compensation       2,934     2,934
Sale of common shares, Amount     $ 17 15,845     15,862
Sale of common shares, Shares     17,239        
Unrealized gain on marketable securities, net of tax         (236)   (236)
Exercise of warrants, Amount     $ 8 14,256     14,264
Exercise of warrants, Shares     8,637        
Net loss           (50,122) (50,122)
Ending balance at Dec. 31, 2015 $ 0 $ 0 $ 694 $ 229,456 $ 0 $ (62,556) $ 167,594
Ending balance, shares at Dec. 31, 2015 0 0 694,396       694,396